Advanced search
Publication Cover
Clinical Pharmacology: Advances and Applications Volume 8, 2016 - Issue
Submit an article Journal homepage
355
Views
10
CrossRef citations to date
0
Altmetric
Review

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

Melanie Davies1 Diabetes Research Centre, University of Leicester;2 Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UKCorrespondence[email protected]
,
Sudesna Chatterjee1 Diabetes Research Centre, University of Leicester;2 Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK
&
Kamlesh Khunti1 Diabetes Research Centre, University of Leicester;2 Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK
Pages 61-81 | Published online: 23 Jun 2016

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Pierre Delanaye & André J. Scheen. (2019) Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 20:3, pages 277-294.
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 211-223.
Read now

Articles from other publishers (8)

Mouhamed Nashawi, Mahmoud S Ahmed, Toka Amin, Mujahed Abualfoul & Robert Chilton. (2021) Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy. World Journal of Cardiology 13:12, pages 676-694.
Crossref
N. V. Belosludtseva, V. S. Starinets & K. N. Belosludtsev. (2021) Effect of Dapagliflozin on the Functioning of Rat Liver Mitochondria In Vitro. Bulletin of Experimental Biology and Medicine 171:5, pages 601-605.
Crossref
Ya. F. Zverev & A. Ya. Rykunova. (2021) Nephroprotective effect of novel oral sugar-reducing medicines: glyflosins. Nephrology (Saint-Petersburg) 25:4, pages 11-22.
Crossref
Gian Paolo Fadini, Olga Disoteo, Riccardo Candido, Paolo Di Bartolo, Luigi Laviola & Agostino Consoli. (2021) Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies. Diabetes Therapy 12:3, pages 781-800.
Crossref
Shang-Feng Tsai & Cheng-Hsu Chen. (2019) Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence. International Journal of Molecular Sciences 20:13, pages 3152.
Crossref
Ghazaleh Behnammanesh, Zane E. Durante, Kelly J. Peyton, Luis A. Martinez-Lemus, Scott M. Brown, Shawn B. Bender & William Durante. (2019) Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation. Frontiers in Pharmacology 10.
Crossref
Salahedeen Abusnana, Mohammad Fargaly, Shaima Hasan Alfardan, Fatema Hasan Al Hammadi, Alaaeldin Bashier, Ghaida Kaddaha, Barbara McGowan, Rita Nawar & Amena Sadiya. (2018) Clinical Practice Recommendations for the Management of Obesity in the United Arab Emirates. Obesity Facts 11:5, pages 413-428.
Crossref
Simona Cernea. (2016) Heart Failure and Chronic Kidney Disease in Type 2 Diabetes. Journal of Interdisciplinary Medicine 1:3, pages 252-258.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.